OA
IMRX icon

Oracle Alpha’s Immuneering IMRX Stock Holding History

Oracle Alpha’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$32.3K Sell
11,165
-629
-5% -$3.52K 0.06% 185
2023
Q4 		$86.7K Buy
+11,794
New +$78.6K 0.11% 243

Other funds holding IMRX

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Oracle Alpha's IMRX Position: Q1 2024 in Review

Oracle Alpha reduced its Immuneering (IMRX) stake by 5.3% in Q1 2024, selling an estimated $3.52K and leaving 11,165 shares worth $32.3K. The position accounts for 0.06% of the portfolio, ranked #185.

Oracle Alpha first reported a position in IMRX in Q4 2023 and has held it in 2 quarters since. The position peaked at $86.7K in Q4 2023. 51 funds tracked by Wall St. Rank hold IMRX as of Q1 2024.

  • Oracle Alpha held 11,165 shares of Immuneering worth $32.3K as of Q1 2024.
  • Oracle Alpha sold 629 Immuneering shares in Q1 2024, an estimated $3.52K.
  • Immuneering made up 0.06% of Oracle Alpha's portfolio in Q1 2024, its #185 holding.
  • Oracle Alpha first reported a position in Immuneering in Q4 2023 and has held it in 2 quarters since.
  • Oracle Alpha's Immuneering position peaked at $86.7K in Q4 2023.
  • 51 funds tracked by Wall St. Rank held Immuneering as of Q1 2024.

Based on Oracle Alpha's 13F filing for Q1 2024, filed 15 May 2024.